ライフサイエンスコーパス: renal dysfunction

1 n and cause end-organ dysfunction, including renal dysfunction.

2 4rKO mice, leads to heightened BP and severe renal dysfunction.

3 lin light chains in the kidney, resulting in renal dysfunction.

4 d renal fibrosis, whereas it did not lead to renal dysfunction.

5 alt-sensitive hypertension solely to primary renal dysfunction.

6 in high diagnostic accuracy in patients with renal dysfunction.

7 laxin reversed DOCA-salt induced cardiac and renal dysfunction.

8 on in death and HF among those with moderate renal dysfunction.

9 tain their clinical utility in patients with renal dysfunction.

10 olerated despite advanced liver and moderate renal dysfunction.

11 r hemolysis and plasma hemoglobin-associated renal dysfunction.

12 final diagnosis in 36% of all patients with renal dysfunction.

13 nd further enhance vascular inflammation and renal dysfunction.

14 function at 1 year in patients with baseline renal dysfunction.

15 ing in patients with ADPKD in the absence of renal dysfunction.

16 increase the mortality rate in patients with renal dysfunction.

17 e being used in patients with some degree of renal dysfunction.

18 ergoing inpatient angiography with worsening renal dysfunction.

19 specifically excluded patients with (severe) renal dysfunction.

20 ein deacetylation and degradation as well as renal dysfunction.

21 represent a therapeutic strategy to prevent renal dysfunction.

22 indication for belatacept was perioperative renal dysfunction.

23 lected liver transplant (LT) candidates with renal dysfunction.

24 e of increased cardiac filling pressures and renal dysfunction.

25 d with less bleeding across the continuum of renal dysfunction.

26 iring cardiopulmonary bypass, no preexisting renal dysfunction.

27 t-liver transplantation) from TAC to SRL for renal dysfunction.

28 ed risk of bleeding across all categories of renal dysfunction.

29 = 30-60 mL/min) and severe (eGFR <30 mL/min) renal dysfunction.

30 partially contribute to TFV and ADV induced renal dysfunction.

31 cted tubular barrier function, and mitigated renal dysfunction.

32 patients with preexistent moderate-to-severe renal dysfunction.

33 role in the pathogenesis of post-transplant renal dysfunction.

34 ataracts, profound learning disabilities and renal dysfunction.

35 e or SLK in liver transplant recipients with renal dysfunction.

36 ppressants) were the strongest predictors of renal dysfunction.

37 ts who experienced skin ulcers, priapism, or renal dysfunction.

38 rdiopulmonary resuscitation before ECMO, and renal dysfunction.

39 from allografts with nonrejection causes of renal dysfunction.

40 eloped hypophosphatemic rickets secondary to renal dysfunction.

41 composite of death, dialysis, or persistent renal dysfunction.

42 or prognosis, especially in individuals with renal dysfunction.

43 iabetes mellitus, myocardial infarction, and renal dysfunction.

44 gher hs-cTnI concentrations and any level of renal dysfunction.

45 slipidemia, atrial fibrillation, anemia, and renal dysfunction.

46 ion, mechanical circulatory support and with renal dysfunction.

47 3-deficient rats develop podocyte injury and renal dysfunction.

48 se disorders in patients without significant renal dysfunction.

49 , hypotension, electrolyte disturbances, and renal dysfunction.

50 y at discharge, anemia, current smoking, and renal dysfunction.

51 nstrated to be effective in mild to moderate renal dysfunction.

52 le of dairy consumption in the prevention of renal dysfunction.

53 ion (FDA) use different criteria to classify renal dysfunction.

54 F enrolled AHF patients (n=360; any EF) with renal dysfunction.

55 reserved renal function in AHF patients with renal dysfunction.

56 ominantly afflicts individuals with advanced renal dysfunction.

57 asma soluble fms-like tyrosine kinase 1, and renal dysfunction.

58 populations, such as women and patients with renal dysfunction.

59 coronary bypass grafting, heart failure, and renal dysfunction.

60 idney allocation to 70% of our patients with renal dysfunction.

61 nalyses identified significant predictors of renal dysfunction: (1) day 3, hematologic malignancy (od

62 up developed rash (13.9% vs 4.2%; P = .002), renal dysfunction (11.4% vs 3.3%; P = .006), and liver f

63 %), skin scarring (5.4%), amputation (3.4%), renal dysfunction (2.6%), and seizures (2.5%).

64 f etiology, severity, duration, and level of renal dysfunction; (2) documentation of degree of nonrev

65 Age, B-type natriuretic peptide level, renal dysfunction, 24-h AHI, CAI, and time with oxygen s

66 gan dysfunction syndrome (34%), shock (28%), renal dysfunction (25%), and acute respiratory distress

67 eglitazar vs 1.7% for placebo, P = .03), and renal dysfunction (7.4% for aleglitazar vs 2.7% for plac

68 82.0%), diabetes (44.8% vs 34.6%), advanced renal dysfunction (8.7% vs 2.3%), prior myocardial infar

69 e tubulointerstitial fibrosis, inflammation, renal dysfunction, activation of NF-kappaB, TGF-beta, an

70 ct mortality in the 752 patients with severe renal dysfunction (adjusted HR: 1.08, 95 % CI: 0.77 to 1

71 Left ventricular size, renal dysfunction, advanced age, and atrial fibrillation

72 t with NAC and NaHCO3 may reduce the risk of renal dysfunction after 30 days.

73 Renal dysfunction after congenital renal mass reduction

74 injury, was the only consistent predictor of renal dysfunction after DCD transplantation (AKI, p < 0.

75 s shown that DGF, encompassing a spectrum of renal dysfunction after kidney transplantation including

76 inst small intestinal injury and hepatic and renal dysfunction after severe intestinal IRI via induct

77 tinine (SCr) would be useful to detect early renal dysfunction after transplantation.

78 >1 prior MI, multivessel disease, diabetes, renal dysfunction (all with ICERs $50,000 to $70,000/QAL

79 onship between both severity and recovery of renal dysfunction and 90-day mortality after major surge

80 e adjustment of the agents in the setting of renal dysfunction and avoidance of the concomitant use o

81 preexisting coronary artery disease reduced renal dysfunction and cardiac injury, potentially result

82 cessive multisystem disorder Arthrogryposis, Renal dysfunction and Cholestasis syndrome caused by VIP

83 sly reported in patients with arthrogryposis renal dysfunction and cholestasis syndrome.

84 served consistently in preclinical models of renal dysfunction and correlated with an increase in Ada

85 n-glyphosate herbicides was likely to induce renal dysfunction and decrease of serum folic acid.

86 ontinuous renal replacement therapy for both renal dysfunction and detoxification.

87 Renal dysfunction and dialysis reduced the rule-in perfo

88 Among patients with renal dysfunction and elevated baseline cTn levels (>/=9

89 ncentrations has been found in subjects with renal dysfunction and even in diabetic patients with mic

90 This association was independent of renal dysfunction and female gender, both of which were

91 vation at a late-stage of CKD abrogated both renal dysfunction and fibrosis, which was associated wit

92 Liver transplant candidates with advanced renal dysfunction and HCC may be considered for SLK.

93 e yet to be fully evaluated in patients with renal dysfunction and in the transplant population.

94 tance phenotype occurs in subjects with mild renal dysfunction and is associated with elevated monocy

95 eatinine has become the preferred marker for renal dysfunction and is readily available in hospital c

96 ential cause of hypertension and progressive renal dysfunction and its clinical and research implicat

97 urinalysis indicate that Hpse2 mutants have renal dysfunction and malnutrition.

98 Calcineurin inhibitors exacerbate renal dysfunction and mammalian target-of-rapamycin inhi

99 n appeared to be associated with lower early-renal dysfunction and no additional risk of hepatic dysf

100 oportion of liver transplant candidates with renal dysfunction and ongoing donor organ shortage.

101 distal to renal artery stenosis is linked to renal dysfunction and poor outcomes.

102 hibition of PTEN with bpV(HOpic) exacerbated renal dysfunction and promoted tubular damage in mice wi

103 ailure and the interactions between baseline renal dysfunction and the effect of randomized treatment

104 Our data illustrate the frequency of renal dysfunction and the powerful prognostic value of l

105 tion cohort and to investigate the impact of renal dysfunction and the value of stroke risk stratific

106 a CD47-blocking antibody protected mice from renal dysfunction and tubular damage compared with an is

107 CD47-knockout mice were protected against renal dysfunction and tubular damage, suggesting that th

108 antagonist BR-4628 can prevent or treat the renal dysfunction and tubular injury induced by IR.

109 en-dependent lung disease, frailty, advanced renal dysfunction, and a high comorbidity score.

110 ytic functions of the endothelium, prevented renal dysfunction, and attenuated nephrosclerosis.

111 latelets from a patient with arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome contai

112 Arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome is a f

113 Arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome is cau

114 patients with heart failure with or without renal dysfunction, and compare it with 2 frequently used

115 prior revascularization, diabetes mellitus, renal dysfunction, and current smoking.

116 ties, such as atherosclerosis, hypertension, renal dysfunction, and diabetes mellitus; as a result, t

117 ular collagen deposition, aortic stiffening, renal dysfunction, and hypertension with age.

118 ed vascular inflammation, aortic stiffening, renal dysfunction, and hypertension; however, adoptive t

119 according to age, sepsis severity, degree of renal dysfunction, and immunocompetence are warranted.

120 conditions involving systemic inflammation, renal dysfunction, and increased adiposity.

121 n and vascular leak, exacerbated hepatic and renal dysfunction, and increased mortality.

122 97) had higher pretest clinical scores, more renal dysfunction, and lower left ventricular ejection f

123 suboptimal, in terms of virologic clearance, renal dysfunction, and mortality.

124 transplantation complications, waiting time, renal dysfunction, and patient age substantially affecte

125 regression analysis, we determined that age, renal dysfunction, and right ventricular systolic pressu

126 Erlotinib on the progression of proteinuria, renal dysfunction, and salt retention in doxorubicin tre

127 tic risk score (CARRS [CVA, albumin, re-HTx, renal dysfunction, and sternotomies]) derived from these

128 C-positive liver transplant recipients with renal dysfunction, and that this regimen can serve as an

129 Patients with AF have a higher incidence of renal dysfunction, and the latter predisposes to inciden

130 Age and renal dysfunction are important determinants of long-ter

131 The DMF cotreatment ameliorated CsA-induced renal dysfunction as evidenced by significant decrease i

132 r early mortality and bilirubin extremes and renal dysfunction as risk factors for late mortality.

133 -sensitive hypertension is not due solely to renal dysfunction, as predicted by the G-C model, but ma

134 The proportion with moderate or severe renal dysfunction at baseline was lower in the TDF than

135 Among patients with moderate or severe renal dysfunction at baseline, renal function improved i

136 We hypothesized that individuals with mild renal dysfunction at increased cardiovascular risk would

137 , blood pressure, lung function, heart rate, renal dysfunction, atrial fibrillation, forced expirator

138 AR should be applied in patients with severe renal dysfunction because postoperative complications we

139 Renal dysfunction before LVAD placement is frequent, and

140 For older patients and for patients with renal dysfunction, bendamustine and rituximab may be a b

141 e responsible for tubular cell apoptosis and renal dysfunction but can be restored using ad-MSC.

142 levels, the levels of cardiac biomarkers, or renal dysfunction but correlated with low systolic blood

143 ited diabetic glomerulosclerosis and reduced renal dysfunction but had no effect on the development o

144 natal day 5, with rapid cystic expansion and renal dysfunction by day 15 and little remaining parench

145 Patients with mild renal dysfunction by FDA criteria have routinely been en

146 tients enrolled onto phase I trials had mild renal dysfunction by FDA criteria.

147 In summary, WISE contributes to renal dysfunction by promoting tubular atrophy and inter

148 who fulfill criteria for nonreversibility of renal dysfunction (by level and duration of renal dysfun

149 atus; and the presence of diabetes mellitus, renal dysfunction, cardiac arrest, cardiogenic shock, an

150 re associated with an increased incidence of renal dysfunction, cardiovascular complications, and de

151 (acetate, propionate, and butyrate) improved renal dysfunction caused by injury.

152 The prevailing explanation that renal dysfunction causes both phenomena or that they are

153 Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome-associated

154 Despite equivalent BP and renal dysfunction, CKDu subjects had a lower PWV than th

155 mong 2813 unselected patients, 447 (16%) had renal dysfunction (defined as Modification of Diet in Re

156 Patients with acute heart failure and renal dysfunction demonstrate variable rise and fall in

157 eedom from coronary angioplasty or stenting, renal dysfunction, diabetes mellitus, CMV infection, or

158 for adult recipients, include hypertension, renal dysfunction, diabetes, bronchiolitis obliterans sy

159 In patients with renal dysfunction, diagnostic accuracy at presentation,

160 e of major adverse kidney events (persistent renal dysfunction, dialysis dependence, and mortality) a

161 esolves, and whether patterns of reversal of renal dysfunction differ among patients with respect to

162 Renal dysfunction, diuretic resistance, and hyponatremia

163 Longer-term renal dysfunction does not appear at an increasing rate

164 The AMR was defined as 3 of 4 criteria: renal dysfunction, donor specific antibody, C4d positivi

165 of IRAK-M did not affect immunopathology and renal dysfunction during early postischemic AKI.

166 n 1962 patients with acute heart failure and renal dysfunction enrolled in the Placebo-Controlled Ran

167 alized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate

168 relationship between cardiac dysfunction and renal dysfunction exists.

169 from metabolic disturbances despite similar renal dysfunction following adenine experimental uremia.

170 n, the remaining 6 patients with uveitis and renal dysfunction fulfilled the criteria of probable TIN

171 es severity and in presence of a significant renal dysfunction (GFR <60 mL/min/1.73 m(2)).

172 scular accident, albumin <3.5 mg/dL, re-HTx, renal dysfunction (glomerular filtration rate <40 mL/min

173 ELD) prioritization of liver recipients with renal dysfunction has significantly increased utilizatio

174 d isolated advanced age, low body weight, or renal dysfunction have a higher risk of stroke or system

175 Smaller patient size, renal dysfunction, hepatic dysfunction, and biventricula

176 The severity and duration of pretransplant renal dysfunction, hepatitis c, diabetes, and other risk

177 orticosteroids, higher perceived cardiac and renal dysfunction, higher perceived posttransplantation

178 ion in patients with acute heart failure and renal dysfunction; however, neither strategy has been ri

179 nd 0, 1, 2, or >/=3 comorbidities, including renal dysfunction, hypertension (HTN), diabetes, coronar

180 In 5 studies that included data on renal dysfunction, ICD implantation was associated with

181 e the first choice in patients with moderate renal dysfunction if they have the appropriate anatomy.

182 renal dysfunction (by level and duration of renal dysfunction, imaging, and pathology findings), wou

183 of abdominal congestion, is correlated with renal dysfunction in advanced congestive heart failure.

184 RAAS inhibitors induce renal dysfunction in both HFREF and HFPEF.

185 ation using serelaxin as a new treatment for renal dysfunction in cirrhosis, although further validat

186 eatment with serelaxin prevented cardiac and renal dysfunction in DOCA-salt rats.

187 calculate eGFR leads to higher estimates of renal dysfunction in HF and a more-accurate categorizati

188 The prevalence and prognostic import of renal dysfunction in HF if the CKD-EPI equation is used

189 ive heart disease but also with the level of renal dysfunction in HFrEF.

190 -based guidelines and uniformity in studying renal dysfunction in liver transplant candidates.

191 Perioperative renal dysfunction in liver transplant recipients complic

192 d male gender are associated with subsequent renal dysfunction in low-risk pediatric patients, especi

193 hat reduced CI is not the primary driver for renal dysfunction in patients hospitalized for HF, irres

194 are needed to understand the true burden of renal dysfunction in patients with beta-thalassemia.

195 nts an underestimated but important cause of renal dysfunction in patients with cholestasis and advan

196 could ameliorate renal vasoconstriction and renal dysfunction in patients with cirrhosis and portal

197 c index (CI) is a significant contributor to renal dysfunction in patients with heart failure (HF).

198 umarate (tenofovir) has been associated with renal dysfunction in people infected with human immunode

199 usses a number of features and mechanisms of renal dysfunction in pulmonary disorders in relation to

200 d restore the microcirculation and alleviate renal dysfunction in renovascular disease.

201 The mechanistic basis for cardiac and renal dysfunction in sepsis is unknown.

202 ant patients and that JCV may have a role in renal dysfunction in some solid organ transplant recipie

203 The result may be clinical renal dysfunction in the form of AKI, progressive CKD, a

204 Over time, however, Cul3 deletion caused renal dysfunction, including hypochloremic alkalosis, di

205 HS, and to determine whether the severity of renal dysfunction influenced the provision of angiograph

206 d according to the pediatric RIFLE (risk for renal dysfunction, injury to the kidney, failure of kidn

207 induced lipid accumulation in the kidney and renal dysfunction, injury, inflammation, and fibrosis.

208 Renal dysfunction is an important prognostic factor in h

209 In patients with heart failure, renal dysfunction is associated with a poor outcome.

210 To test whether mild renal dysfunction is associated with an increase in a le

211 In patients with mild HF, moderate renal dysfunction is associated with higher risk of deat

212 Renal dysfunction is associated with lower survival in p

213 Renal dysfunction is frequent in liver cirrhosis and is

214 Renal dysfunction is intricately linked to aortic stenos

215 active renal vasculitis from other causes of renal dysfunction is lacking, with a kidney biopsy often

216 ischemia/reperfusion (I/R)-induced AKI, when renal dysfunction is maximal, would accelerate recovery

217 Outside hospital, renal dysfunction is more strongly associated with morta

218 in patients with more advanced cirrhosis and renal dysfunction is required.

219 rt failure considered for LVAD implantation, renal dysfunction is reversible and likely related to po

220 We hypothesized that renal dysfunction is underpinned by a reduced contributi

221 to cardiac pathologies before development of renal dysfunction is unknown.

222 t of orthotopic liver transplantation (OLT), renal dysfunction is used as a criterion for simultaneou

223 months after transplantation, she developed renal dysfunction, leading to a reduction in Tac and the

224 Encephalopathy, hepatic, and renal dysfunction manifested later than cardiovascular a

225 These results suggest that severe renal dysfunction may be marginally reversible after LT,

226 different phenotypes of patients with acute renal dysfunction may be present, which has ramification

227 Depression and renal dysfunction may increase the risk of VAD infection

228 moderate, or refractory) and to hepatic and renal dysfunctions (MELD score </= or >15 and KDOQI stag

229 In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dos

230 erminal probrain natriuretic peptide levels, renal dysfunction, neurohumoral activation, myocardial n

231 patient was not undergoing dialysis for her renal dysfunction, nor was she receiving steroids for CO

232 Renal dysfunction occurred in 20 (51%) of 39 by end of t

233 Renal dysfunction occurred in 461 (24.3%).

234 .049), a significant increase in the risk of renal dysfunction, odds ratio 4.74 (95% CI, 2.48-9.08; p

235 al function were not predictors of worsening renal dysfunction on days 3, 7, and EOT.

236 odynamic factors, such as high uric acid and renal dysfunction, on changes in the left ventricular ma

237 ts with heart failure and accompanied severe renal dysfunction or advanced heart disease.

238 s prognostic utility in patients with severe renal dysfunction or advanced heart failure.

239 Renal dysfunction or decline in renal function is a know

240 alignancy (OR, 1.58; 95% CI, 1.05-2.37), and renal dysfunction (OR for estimated glomerular filtratio

241 ere patient age (OR, 1.17) and postoperative renal dysfunction (OR, 16.33).

242 95% CI: 0.31 to 0.76 per mg/dl of albumin), renal dysfunction (OR: 2.1, 95% CI: 1.4 to 3.2 per mg/dl

243 association between hemoglobin and brain or renal dysfunction, or ICU mortality.

244 OR (odds ratio) = 1.64 (95% CI: 1.21, 2.21); renal dysfunction: OR = 2.05 (1.39, 3.05); urinary tract

245 tion correlated with both the development of renal dysfunction over the 72 hours after urine collecti

246 often with shock, pulmonary infiltrates, and renal dysfunction (p < 0.0001 for all comparisons).

247 d brain dysfunction (p = 0.69 for delirium), renal dysfunction (p = 0.30), or ICU mortality (p = 0.95

248 iated with development of ascites (P=0.057), renal dysfunction (P=0.004), bacterial infections (P=0.0

249 to be an attractive option for patients with renal dysfunction, peripheral arterial disease, or follo

250 line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other com

251 versus 51.4+/-11.8 years; P<0.001), had more renal dysfunction, prior cancer, and smoking.

252 CXCL16 knockout mice exhibited less severe renal dysfunction, proteinuria, and fibrosis after DOCA-

253 who had pre-LT kidney biopsy for unexplained renal dysfunction, proteinuria, and hematuria were retro

254 and had a higher prevalence of hypertension, renal dysfunction, pulmonary disease, and vascular disea

255 Because patients with renal dysfunction (RD) frequently present with increased

256 Identifying reversible renal dysfunction (RD) in the setting of heart failure i

257 lipocalin (NGAL) can predict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF

258 ients had lower rates of DGF (5% vs 20%) and renal dysfunction-related readmissions (10% vs 27.5%) (P

259 However, predicting which donors will have renal dysfunction remains challenging, particularly amon

260 ent mice had significantly less albuminuria, renal dysfunction, renal cortical NF-kappaB activation,

261 requiring reexploration and the incidence of renal dysfunction requiring dialysis were higher in pati

262 as been documented in patients with CHD with renal dysfunction, restrictive lung disease, anemia, and

263 importantly, OPEN in patients with moderate renal dysfunction resulted in 5.2 times higher risk of d

264 OPEN in patients with moderate renal dysfunction resulted in significantly higher morta

265 has significantly increased the incidence of renal dysfunction seen among patients undergoing liver t

266 e [CHD], unrepaired CHD vs. cardiomyopathy), renal dysfunction (severe, mild-moderate vs. normal) and

267 ff levels, which are higher in patients with renal dysfunction, should be considered.

268 presence or absence of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced N

269 r age, vascular surgery, bleeding event, and renal dysfunction strongly predict long-term mortality a

270 e exhibited more severe thrombocytopenia and renal dysfunction than TM(wt/wt) mice.

271 tanding of epigenetic mechanisms involved in renal dysfunction that in turn may lead to identificatio

272 gnosed by a pediatric nephrologist as having renal dysfunction that suggested acute interstitial neph

273 After excluding other causes of renal dysfunction, the remaining 6 patients with uveitis

274 than 1 year after LT alone (n = 8) developed renal dysfunction thereafter.

275 However, in patients with severe renal dysfunction, these outcomes were similarly high in

276 Among patients with no or mild renal dysfunction, those receiving TDF were more likely

277 effects on renal fibrosis and the resultant renal dysfunction, thus it could represent a therapeutic

278 AKI mouse model, in which gallein attenuated renal dysfunction, tissue damage, fibrosis, inflammation

279 such as ultrafiltration, may also result in renal dysfunction to a greater extent than medical thera

280 ple diagnostic screening tools for detecting renal dysfunction to diagnose TINU syndrome in young pat

281 ly invasive approach in patients with severe renal dysfunction to ensure that all patients who may be

282 motherapy, even among patients with advanced renal dysfunction, to delay progression to ESRD and prev

283 In future oncology renal dysfunction trials based on the FDA classification

284 of stage III (moderate) or stage IV (severe) renal dysfunction was 72%, 64%, and 75% for treatment wi

285 Relative to normal function, mild renal dysfunction was associated with a statistically si

286 o symptomatic (stage C) HF over 3 years, and renal dysfunction was associated with this progression i

287 Renal dysfunction was categorized as mild (estimated glo

288 Renal dysfunction was highly prevalent in patients with

289 However, renal dysfunction was less persistent in these animals.

290 Baseline renal dysfunction was more prevalent in older patients w

291 erator characteristic curve in patients with renal dysfunction was only slightly lower than in patien

292 After IRI, renal dysfunction was prolonged after the high-dose gall

293 intrarenal inflammation, tubular damage, and renal dysfunction were abrogated in mice deficient in My

294 ge, low systolic blood pressure, anemia, and renal dysfunction were identified in both acute and chro

295 interval, 3.95-8.15) and measures of hepatic/renal dysfunction were inversely associated with the rec

296 abetes mellitus, higher body mass index, and renal dysfunction were more common among those with LVDD

297 e-derived cTn cutoff levels in patients with renal dysfunction were significantly higher compared wit

298 ies (obesity, anemia, diabetes mellitus, and renal dysfunction) were each associated with unique clin

299 nts, 151 underwent a renal biopsy because of renal dysfunction, whereas the 218 remaining showed a st

300 urvival benefit in patients with and without renal dysfunction, yet renal impairment is an important